<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002233</url>
  </required_header>
  <id_info>
    <org_study_id>264K</org_study_id>
    <secondary_id>COLA 2012</secondary_id>
    <nct_id>NCT00002233</nct_id>
  </id_info>
  <brief_title>A Study of a Combination of Four Drugs in Patients With Recent HIV Infection</brief_title>
  <official_title>A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe to give a combination of four anti-HIV&#xD;
      drugs to patients recently infected with HIV who have never received anti-HIV treatment. The&#xD;
      effects of this combination of drugs on the immune system and the level of HIV in the body&#xD;
      are studied also. The four-drug combination includes lamivudine, abacavir, amprenavir, and&#xD;
      indinavir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive a four-drug regimen consisting of two nucleoside reverse transcriptase&#xD;
      inhibitors (3TC and abacavir) and two protease inhibitors (amprenavir and indinavir) for a&#xD;
      minimum of 48 weeks. At specified time points, patients undergo physical assessments and&#xD;
      efficacy evaluations which include plasma HIV-1 RNA measurements and CD4 cell counts.&#xD;
      Depending on the immunologic and virologic status of the patient, further testing may be done&#xD;
      to determine whether quadruple drug therapy can attain undetectable viral levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed with caution and/or careful monitoring:&#xD;
&#xD;
          -  Drugs which may interact at CYP3A4 (e.g., alprazolam, carbamazepine, codeine,&#xD;
             clarithromycin, dapsone, diazepam, diltiazem, erythromycin, estrogens, fluvastatin,&#xD;
             glucocorticoids, imipramine, lidocaine, lovastatin, nifedipine, phenobarbital,&#xD;
             phenytoin, simvastatin, and warfarin).&#xD;
&#xD;
          -  Drugs that inhibit cytosolic alcohol dehydrogenase (e.g., ethanol, disulfiram,&#xD;
             chlorzoxazone, chlorpromazine, isoniazid, and chloral hydrate).&#xD;
&#xD;
          -  Drugs known to affect renal tubular secretion (e.g., probenecid or cimetidine), cause&#xD;
             liver toxicity, or induce myelosuppression.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented and confirmed acute HIV-1 infection.&#xD;
&#xD;
          -  No prior exposure to antiretroviral treatment.&#xD;
&#xD;
          -  Ability to comply with the investigational nature of the study for a minimum of 48&#xD;
             weeks.&#xD;
&#xD;
          -  Consent of parent or guardian if under the age of 18.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  A clinical diagnosis of AIDS, excluding CD4+ cell counts less than 200/mm3.&#xD;
&#xD;
          -  A serious medical condition such as diabetes, congestive heart failure,&#xD;
             cardiomyopathy, or other cardiac dysfunction that, in the opinion of the investigator,&#xD;
             compromises the safety of the patient.&#xD;
&#xD;
          -  Institutionalized or mentally disabled.&#xD;
&#xD;
          -  Inability to comply with the dosing schedule and protocol evaluations for reasons&#xD;
             other than those specified.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Concurrent therapy with rifampin, rifabutin, terfenadine, astemizole, ketoconazole,&#xD;
             itraconazole, cisapride, triazolam, midazolam, quinidine, amiodarone, and/or&#xD;
             ergotamine/dihydroergotamine-containing regimens.&#xD;
&#xD;
          -  Foscarnet or therapy with other agents with documented in vitro or in vivo activity&#xD;
             against HIV-1.&#xD;
&#xD;
          -  Medications known to induce or inhibit hepatic cytochrome P450 enzyme systems.&#xD;
&#xD;
          -  Vitamin E supplements.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Dependence on blood transfusions.&#xD;
&#xD;
          -  Other investigational treatments.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  A history of clinically relevant pancreatitis or hepatitis within 6 months of study&#xD;
             entry.&#xD;
&#xD;
          -  A history of inflammatory bowel disease or malignancy, intestinal ischemia,&#xD;
             malabsorption, or other gastrointestinal dysfunction that might interfere with drug&#xD;
             absorption or render the patient unable to take oral medication.&#xD;
&#xD;
          -  An unexplained fever above 38.5 Celsius for more than 14 days within 30 days of study&#xD;
             entry.&#xD;
&#xD;
          -  A history of coagulopathy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior exposure to antiretroviral therapy.&#xD;
&#xD;
          -  Therapy with immunomodulating agents such as systemic corticosteroids, interleukins,&#xD;
             thalidomide, anti-cytokine agents or interferons, cytotoxic chemotherapeutic agents,&#xD;
             or anti-oxidants within 30 days of study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Radiation therapy within 30 days of study entry.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Alcohol or illicit drug use which, in the opinion of the investigator, may interfere with&#xD;
        ability to comply with the dosing schedule and protocol evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hosp / Family Healthcare Ctr at SSTAR</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

